← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › IMMUNE SERA AND IMMUNOGLOBULINS › IMMUNOGLOBULINS › Immunoglobulins, normal human
immunoglobulins, normal human, for extravascular adm.
J06BA01
Forms & Strengths
- Solution for subcutaneous injection: 16.5% - 20% (165 mg/mL - 200 mg/mL)
Adult Dosing
- Primary immunodeficiency: Subcutaneous initial weekly dose is calculated based on prior IVIG dose (typically 1:1 conversion), starting 1 week after last IV infusion.
- Maintenance: Subcutaneous 100 mg/kg to 200 mg/kg weekly, adjusted based on clinical response and serum IgG trough levels.
Pediatric Dosing
- Primary immunodeficiency (pediatric patients over 2 years): Same as adult dosing on a mg/kg basis; initial weekly dose matches prior IVIG dose converted, maintenance 100 mg/kg to 200 mg/kg weekly adjusted to trough levels.
Indications
- Replacement therapy in primary immunodeficiency syndromes (e.g., congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome).
Mechanism of Action
- Provides passive immunity by restoring abnormal or deficient IgG antibody repertoires, neutralizing microorganisms and toxins, and modulating the immune system through Fc-receptor blockade and anti-idiotypic mechanisms.
Contraindications
- Anaphylactoid or severe systemic hypersensitivity reactions to human immune globulin.
- IgA deficient patients with antibodies against IgA and a history of hypersensitivity.
Adverse Reactions
- Local infusion site reactions (erythema, swelling, pruritus, pain, bruising)
- Headache
- Fatigue
- Pyrexia
- Nausea
- Aseptic meningitis syndrome
- Thromboembolic events
- Hypersensitivity and anaphylactic reactions
Drug Interactions
- Live virus vaccines (measles, mumps, rubella, varicella): Antibodies in immune globulin may impair the efficacy of live attenuated vaccines; defer vaccination for up to 3 to 11 months post-infusion.
Curated Content: Needs Vetting Before Put to Clinical Use